GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

UCB Wins License from Lonza to GS Gene Expression System

  • Lonza granted UCB a nonexclusive, worldwide license to their GS Gene Expression System™ (GS: glutamine synthetase).

    The research evaluation agreement covers the use of the technology for R&D. An option to obtain a license to use the system for commercial purposes is included in the agreement.

    “We believe that having UCB select the GS Gene Expression System underscores the importance of this technology for the efficient production of therapeutic antibodies and recombinant proteins,” says Karen Fallen, commercial licensing manager at Lonza.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?